{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:11:53Z","timestamp":1790435513717,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.jaad.2004.06.013","type":"journal-article","created":{"date-parts":[[2004,12,30]],"date-time":"2004-12-30T07:22:15Z","timestamp":1104391335000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Diagnosis and treatment of psoriatic arthritis"],"prefix":"10.1016","volume":"52","author":[{"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard S.","family":"Goffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2004.06.013_bib1","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib2","series-title":"Vital and health statistics: current estimates from the National Health Interview Survey, 1996","year":"2003"},{"key":"10.1016\/j.jaad.2004.06.013_bib3","unstructured":"National Psoriasis Foundation. About psoriasis Web page. Available at: http:\/\/www.psoriasis.org. Accessed November 12, 2003."},{"key":"10.1016\/j.jaad.2004.06.013_bib4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/13543784.9.7.1511","article-title":"Psoriatic arthritis","volume":"9","author":"Gladman","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2004.06.013_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/PL00011173","article-title":"Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution","volume":"19","author":"ElKayam","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0889-857X(05)70044-2","article-title":"Psoriatic arthritis","volume":"24","author":"Gladman","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2004.06.013_bib7","unstructured":"National Psoriasis Foundation. Benchmark survey on psoriasis and psoriatic arthritis. Available at: http:\/\/www.psoriasis.org\/news\/news\/2001\/200104_npfsurvey.php. Accessed August 9, 2003."},{"key":"10.1016\/j.jaad.2004.06.013_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","article-title":"Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis","volume":"45","author":"Husted","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib9","first-page":"1115","article-title":"Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis","volume":"19","author":"Buskila","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib10","first-page":"127","article-title":"Psoriatic arthritis (PSA)\u2014an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib11","first-page":"1041","article-title":"Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis","volume":"28","author":"Rahman","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib12","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death","volume":"41","author":"Gladman","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0190-9622(96)90676-3","article-title":"Utilization of outpatient care for psoriasis","volume":"35","author":"Stem","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7","article-title":"Psoriatic arthritis: a unified concept twenty years on","volume":"42","author":"McGonagle","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1523-1747.ep12297659","article-title":"Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores","volume":"107","author":"Fleischer","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1067\/mjd.2001.114592","article-title":"Physical and psychologic measures are necessary to assess overall psoriasis severity","volume":"45","author":"Kirby","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0049-0172(79)80001-3","article-title":"Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients","volume":"9","author":"Kammer","year":"1979","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0190-9622(97)80214-9","article-title":"The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort","volume":"36","author":"McKenna","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib22","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib23","first-page":"1045","article-title":"Remission in psoriatic arthritis","volume":"28","author":"Gladman","year":"2001","journal-title":"J Rheumatol"},{"issue":"Suppl 54","key":"10.1016\/j.jaad.2004.06.013_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2133.1999.140S54001.x","article-title":"Recent developments in the understanding of the pathogenesis of psoriasis","volume":"140","author":"Ortonne","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002281-199707000-00004","article-title":"Clinical, immunopathogenic, and therapeutic aspects of psoriatic arthritis","volume":"9","author":"FitzGerald","year":"1997","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s002560050500","article-title":"The prevalence of sacroiliitis in psoriatic arthritis: new perspectives from a large, multicenter cohort. A Department of Veterans Affairs Cooperative Study","volume":"28","author":"Battistone","year":"1999","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.jaad.2004.06.013_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ard.57.3.135","article-title":"Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis?","volume":"57","author":"Helliwell","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/27.2.133","article-title":"The clinical spectrum of psoriatic spondylitis","volume":"27","author":"Scarpa","year":"1988","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib31","first-page":"69","article-title":"Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report","volume":"146","author":"Biondi","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.jaad.2004.06.013_bib32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/rheumatology\/37.5.480","article-title":"Skin and joint disease in psoriatic arthritis: what is the link?","volume":"37","author":"Pitzalis","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/107110079101200107","article-title":"Psoriatic arthritis of the foot and ankle: analysis of joint involvement and diagnostic errors","volume":"12","author":"Hammerschlag","year":"1991","journal-title":"Foot Ankle"},{"key":"10.1016\/j.jaad.2004.06.013_bib34","first-page":"1752","article-title":"Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies","volume":"26","author":"Cohen","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0738-081X(95)93816-7","article-title":"The puzzling genetics of psoriasis","volume":"13","author":"Traupe","year":"1995","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib36","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/hmg\/7.10.1537","article-title":"The genetics of psoriasis: a complex disorder of the skin and immune system","volume":"7","author":"Bhalerao","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaad.2004.06.013_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00002281-200107000-00005","article-title":"Psoriatic arthritis: clinical aspects, genetics, and the role of T cells","volume":"13","author":"Hohler","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib38","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0190-9622(97)80394-5","article-title":"The genetics of psoriasis","volume":"37","author":"Henseler","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib39","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2133.1997.19892070.x","article-title":"Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands","volume":"137","author":"Swanbeck","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.32.3.181","article-title":"Familial occurrence of psoriatic arthritis","volume":"32","author":"Moll","year":"1973","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00000441-199810000-00008","article-title":"Insights into the pathogenesis of psoriasis and psoriatic arthritis","volume":"316","author":"Espinoza","year":"1998","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaad.2004.06.013_bib42","first-page":"586","article-title":"HLA antigens in psoriatic arthritis","volume":"13","author":"Gladman","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/ard.46.3.184","article-title":"Psoriatic arthritis: clinical subgroups and histocompatibility antigens","volume":"46","author":"McHugh","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0198-8859(98)00123-2","article-title":"HLA-C locus alleles in patients with psoriatic arthritis (PsA)","volume":"60","author":"Gladman","year":"1999","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib45","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/1529-0131(199905)42:5<1010::AID-ANR21>3.0.CO;2-H","article-title":"The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw\u22170602 in psoriasis","volume":"42","author":"Gonzalez","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00002281-200107000-00002","article-title":"Cytokine gene polymorphisms relevant for the spondyloarthropathies","volume":"13","author":"Rudwaleit","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib47","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1523-1747.1998.00213.x","article-title":"Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p","volume":"110","author":"Burden","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib48","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s004399900182","article-title":"A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach","volume":"105","author":"Samuelsson","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.jaad.2004.06.013_bib49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07853899509031956","article-title":"Genetic locus for psoriasis identified","volume":"27","author":"Bowcock","year":"1995","journal-title":"Ann Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/ard.40.1.66","article-title":"Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis","volume":"40","author":"Laurent","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib51","first-page":"422","article-title":"Immunofluorescence studies for immunoglobulins and complement C3 in synovial joint membranes in psoriatic arthritis","volume":"29","author":"Fyrand","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib52","first-page":"221","article-title":"IgA-containing immune complexes in patients with psoriatic arthritis","volume":"2","author":"Hall","year":"1984","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.38.6.526","article-title":"Antinuclear antibodies in ankylosing spondylitis, psoriatic arthritis, and psoriasis","volume":"38","author":"Rosenberg","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib54","first-page":"31","article-title":"Antinuclear antibodies in psoriatic arthritis and its subgroups","volume":"146","author":"Calzavara","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"10.1016\/j.jaad.2004.06.013_bib55","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/art.1780340909","article-title":"Autoantibodies to human stress proteins. A survey of various rheumatic and other inflammatory diseases","volume":"34","author":"Jarjour","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/ard.53.6.391","article-title":"Increased IgA antibodies to cytokeratins in the spondyloarthropathies","volume":"53","author":"Borg","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0049-0172(97)80019-4","article-title":"Antibodies to cytokeratins in inflammatory arthropathies","volume":"27","author":"Borg","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib58","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0190-9622(99)70078-2","article-title":"Antiperinuclear factor in psoriatic arthropathy","volume":"40","author":"Calzavara-Pinton","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2230.2001.00792.x","article-title":"Pathogenesis of psoriatic arthritis","volume":"26","author":"Fearon","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0167-5699(98)01381-4","article-title":"The pathogenesis of psoriasis: immunological facts and speculations","volume":"20","author":"Bos","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.jaad.2004.06.013_bib61","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nm0595-442","article-title":"Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis","volume":"1","author":"Gottlieb","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib62","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archderm.135.9.1104","article-title":"The immunologic and genetic basis of psoriasis","volume":"135","author":"Nickoloff","year":"1999","journal-title":"Arch Dermatol"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib63","first-page":"S90","article-title":"Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): Results of a phase 3 multicenter clinical trial","volume":"44","author":"Mease","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.jaad.2004.06.013_bib64","first-page":"S91","article-title":"Alefacept (LFA3-IgG1 fusion protein, LFA3TIP) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis","volume":"44","author":"Dinant","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib65","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/1523-1747.ep12371678","article-title":"T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation","volume":"101","author":"Strange","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/eji.1830240315","article-title":"T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products","volume":"24","author":"Prinz","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib67","first-page":"1117","article-title":"Predominance of CD8+ T lymphocytes in psoriatic arthritis","volume":"26","author":"Costello","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0198-8859(99)00034-8","article-title":"Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis","volume":"60","author":"Tassiulas","year":"1999","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib69","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.4049\/jimmunol.166.4.2878","article-title":"Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven","volume":"166","author":"Costello","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib70","first-page":"115","article-title":"Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis","volume":"11","author":"Mussi","year":"1997","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaad.2004.06.013_bib71","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor\u2013alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.06.013_bib73","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with antitumour necrosis factor\u2013alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Ogilvie","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib74","first-page":"719","article-title":"Possible involvement of group A streptococci in the pathogenesis of psoriatic arthritis","volume":"9","author":"Vasey","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1399-0039.1996.tb02687.x","article-title":"Significance of antibodies to streptococcal M protein in psoriatic arthritis and their association with HLA-A\u22170207","volume":"48","author":"Muto","year":"1996","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jaad.2004.06.013_bib76","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/1529-0131(199910)42:10<2055::AID-ANR5>3.0.CO;2-A","article-title":"V2 regions of 16S ribosomal RNA used as a molecular marker for the species identification of streptococci in peripheral blood and synovial fluid from patients with psoriatic arthritis","volume":"42","author":"Wang","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib77","first-page":"621","article-title":"High levels of antipeptidoglycan antibodies in psoriatic and other seronegative arthritides","volume":"17","author":"Rahman","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib78","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00002281-199002040-00004","article-title":"Psoriatic arthritis","volume":"2","author":"Gladman","year":"1990","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib79","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0889-857X(21)00088-0","article-title":"Psoriasis and psoriatic arthritis associated with human immunodeficiency virus infection","volume":"17","author":"Arnett","year":"1991","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2004.06.013_bib80","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0889-857X(21)00722-5","article-title":"There is an association between human immunodeficiency virus infection and spondyloarthropathies","volume":"18","author":"Espinoza","year":"1992","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2004.06.013_bib81","first-page":"1699","article-title":"Psoriatic arthritis and human immunodeficiency virus infection in Zambia","volume":"27","author":"Njobvu","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00271870","article-title":"Aspects of the spectrum, prevalence and disease susceptibility determinants of Reiter's syndrome and related disorders associated with HIV infection","volume":"9","author":"Brancato","year":"1989","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2004.06.013_bib83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/03009748809102943","article-title":"Implications from the occurrence of Reiter's syndrome and related disorders in association with advanced HIV infection","volume":"74","author":"Winchester","year":"1988","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.jaad.2004.06.013_bib84","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9629(15)40413-6","article-title":"Clinical aspects of the spondyloarthropathies","volume":"316","author":"Gladman","year":"1998","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaad.2004.06.013_bib85","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(97)00410-5","article-title":"Office evaluation of the patient with musculoskeletal complaints","volume":"102","author":"Barth","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib86","series-title":"Textbook of rheumatology","first-page":"974","article-title":"Psoriatic arthritis","author":"Michet","year":"1993"},{"key":"10.1016\/j.jaad.2004.06.013_bib87","series-title":"Arthritis and allied conditions: a textbook of rheumatology","first-page":"1345","article-title":"Psoriatic arthritis","author":"Bennet","year":"2001"},{"key":"10.1016\/j.jaad.2004.06.013_bib88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5435\/00124635-200301000-00008","article-title":"Ordering and interpreting rheumatologic laboratory tests","volume":"11","author":"Gardner","year":"2003","journal-title":"J Am Acad Orthop Surg"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib89","first-page":"S178","article-title":"A comparison of the ESR, CRP, serum amyloid A and cartilage oligomeric matrix protein in assessing inflammation and predicting radiological outcome in early psoriatic arthritis","volume":"48","author":"Kane","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib90","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/ard.47.5.386","article-title":"Psoriatic spondyloarthropathy: a long term prospective study","volume":"47","author":"Hanly","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib91","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00002281-200007000-00007","article-title":"Psoriatic arthritis: evolving concepts","volume":"12","author":"Scarpa","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00002281-199807000-00004","article-title":"Psoriatic arthritis","volume":"10","author":"Salvarani","year":"1998","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib93","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/40.3.342","article-title":"Tumoral enthesopathy in psoriasis","volume":"40","author":"Stevens","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2004.06.013_bib94","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/rheumatology\/38.4.332","article-title":"Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis","volume":"38","author":"Marsal","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2004.06.013_bib95","first-page":"446","article-title":"Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients","volume":"66","author":"Fourni\u00e9","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.jaad.2004.06.013_bib96","first-page":"730","article-title":"HLA markers and progression in psoriatic arthritis","volume":"25","author":"Gladman","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0025-6196(11)62116-2","article-title":"Topical therapies for localized psoriasis","volume":"76","author":"Witman","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2004.06.013_bib98","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3949\/ccjm.67.2.105","article-title":"Psoriasis: a clinical update on diagnosis and new therapies","volume":"67","author":"Camisa","year":"2000","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib99","first-page":"2409","article-title":"Progression in psoriatic arthritis: role of time varying clinical indicators","volume":"26","author":"Gladman","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000212","article-title":"Interventions for psoriatic arthritis","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2004.06.013_bib101","first-page":"1922","article-title":"Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?","volume":"27","author":"Lacaille","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib102","first-page":"241","article-title":"Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib103","first-page":"229","article-title":"Clinical liver disease in patients with rheumatoid arthritis taking methotrexate","volume":"19","author":"Phillips","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib104","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0049-0172(97)80035-2","article-title":"Therapy with cyclosporine in psoriatic arthritis","volume":"27","author":"Olivieri","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib106","first-page":"609","article-title":"Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs","volume":"15","author":"Spadaro","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib107","first-page":"1957","article-title":"The use of sulfasalazine in psoriatic arthritis: a clinic experience","volume":"25","author":"Rahman","year":"1998","journal-title":"J Rheumatol"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib108","first-page":"S170","article-title":"A randomised, double-blind, placebo controlled multi-centre trial of combination therapy with methotrexate plus cyclosporin vs methotrexate plus placebo in patients with active psoriatic arthritis (PsA)","volume":"48","author":"Fraser","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib109","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Treatment of Psoriatic Arthritis Study Group Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib110","first-page":"28","article-title":"Cytokines in rheumatoid arthritis","volume":"43","author":"Koch","year":"1995","journal-title":"J Investig Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib111","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib112","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s004030050299","article-title":"An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis","volume":"290","author":"Terajima","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2004.06.013_bib113","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib114","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.49.9.665","article-title":"Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis","volume":"49","author":"Tetta","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0896-8411(88)90006-6","article-title":"Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis","volume":"1","author":"Husby","year":"1988","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaad.2004.06.013_bib116","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2249.1992.tb06939.x","article-title":"Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta","volume":"89","author":"Cooper","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaad.2004.06.013_bib117","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"10.1016\/j.jaad.2004.06.013_bib118","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2004.06.013_bib119","series-title":"Enbrel\u00ae (etanercept) [package insert]","year":"2004"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2004.06.013_bib120","article-title":"Etanercept (Enbrel) in patients with psoriatic arthritis and psoriasis: continued observations","volume":"62","author":"Mease","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.jaad.2004.06.013_bib121","first-page":"S196","article-title":"Etanercept (ENBREL\u00ae) inhibits radiographic progression in patients with psoriatic arthritis","volume":"46","author":"Ory","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.jaad.2004.06.013_bib122","article-title":"Etanercept (ENBREL) improves health-related quality of life in patients with psoriatic arthritis","volume":"46","author":"Wanke","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib123","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.jaad.2004.06.013_bib124","first-page":"S196","article-title":"Etanercept (ENBREL) inhibits radiographic progression in patients with psoriatic arthritis","volume":"46","author":"Mease","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2004.06.013_bib125","article-title":"Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis","volume":"62","author":"Ory","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2004.06.013_bib126","unstructured":"Ritchlin CT, Haas-Smith SA, Shao T, Durham R, Monu J, Suk Seo G, et al. Etanercept lowers the frequency of circulating osteoclast precursors (OCP) and improves bone marrow edema in patients with erosive psoriatic arthritis [abstract]. Presented at: 67th Annual Scientific Meeting of the American College of Rheumatology; October 23-28, 2003; Orlando (FL)."},{"key":"10.1016\/j.jaad.2004.06.013_bib127","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib128","first-page":"S167","article-title":"Sustained improvement in activities of daily living in patients with psoriatic arthritis treated with etanercept","volume":"48","author":"Mease","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib129","first-page":"S424","article-title":"Etanercept plus a patient education and support system improve health-related quality of life in rheumatoid arthritis patients in a clinical practice setting","volume":"48","author":"Martin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib130","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib131","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2004.06.013_bib132","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2004.06.013_bib133","unstructured":"Antoni C, Smolen J, The IMPACT Study Group. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Poster presented at: 61st Annual Meeting of the American Academy of Dermatology; March 21-26, 2003; San Francisco. Poster 9."},{"key":"10.1016\/j.jaad.2004.06.013_bib134","first-page":"S122","article-title":"Infliximab for psoriasis and psoriatic arthritis","volume":"20","author":"Antoni","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib135","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.10671","article-title":"Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation","volume":"47","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib136","first-page":"S381","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"47","author":"Antoni","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1016\/j.jaad.2004.06.013_bib137","first-page":"S265","article-title":"The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"47","author":"Antoni","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib138","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","article-title":"Rational use of new and existing disease-modifying agents in rheumatoid arthritis","volume":"134","author":"Kremer","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib139","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2004.06.013_bib140","series-title":"Remicade [package insert]","year":"2002"},{"key":"10.1016\/j.jaad.2004.06.013_bib141","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib142","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJM199912093412407","article-title":"Inflammatory skin diseases, T cells, and immune surveillance","volume":"341","author":"Robert","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2004.06.013_bib143","unstructured":"FaxWatch [press release]. Genentech, Xoma's Raptiva fails to meet endpoint in Phase II psoriatic arthritis trial. March 22, 2004."},{"key":"10.1016\/j.jaad.2004.06.013_bib144","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1067\/mjd.2000.106515","article-title":"Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis","volume":"43","author":"Krueger","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib145","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1046\/j.1523-1747.2000.00143.x","article-title":"Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides","volume":"115","author":"Mehta","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2004.06.013_bib146","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.0007-0963.2001.04529.x","article-title":"Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy","volume":"146","author":"Iyer","year":"2002","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220401607X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220401607X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:35:35Z","timestamp":1759268135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096220401607X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":146,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S019096220401607X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2004.06.013","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2004.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}